Amyloid-β specific regulatory T cells attenuate Alzheimer's disease pathobiology in APP/PS1 mice.
Alzheimer’s disease
Amyloid beta
Antigen specific
Immunotherapy
T cell receptor
Treg cell therapy
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
received:
29
05
2023
accepted:
04
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
epublish
Résumé
Regulatory T cells (Tregs) maintain immune tolerance. While Treg-mediated neuroprotective activities are now well-accepted, the lack of defined antigen specificity limits their therapeutic potential. This is notable for neurodegenerative diseases where cell access to injured brain regions is required for disease-specific therapeutic targeting and improved outcomes. To address this need, amyloid-beta (Aβ) antigen specificity was conferred to Treg responses by engineering the T cell receptor (TCR) specific for Aβ (TCR TCR TCR TCR
Sections du résumé
BACKGROUND
BACKGROUND
Regulatory T cells (Tregs) maintain immune tolerance. While Treg-mediated neuroprotective activities are now well-accepted, the lack of defined antigen specificity limits their therapeutic potential. This is notable for neurodegenerative diseases where cell access to injured brain regions is required for disease-specific therapeutic targeting and improved outcomes. To address this need, amyloid-beta (Aβ) antigen specificity was conferred to Treg responses by engineering the T cell receptor (TCR) specific for Aβ (TCR
METHODS
METHODS
TCR
RESULTS
RESULTS
TCR
CONCLUSIONS
CONCLUSIONS
TCR
Identifiants
pubmed: 38111016
doi: 10.1186/s13024-023-00692-7
pii: 10.1186/s13024-023-00692-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Subventions
Organisme : NINDS NIH HHS
ID : 2R01 NS034239
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954–63.
pubmed: 34083813
doi: 10.1038/s41591-021-01382-x
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.
pubmed: 23477989
doi: 10.1016/S1474-4422(13)70044-9
Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S12–8.
pubmed: 16772751
doi: 10.1097/01.wad.0000213804.59187.2d
Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8:e12295.
pubmed: 35516416
doi: 10.1002/trc2.12295
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7.
pubmed: 10408445
doi: 10.1038/22124
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408:979–82.
pubmed: 11140685
doi: 10.1038/35050110
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408:982–5.
pubmed: 11140686
doi: 10.1038/35050116
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46–54.
pubmed: 12847155
doi: 10.1212/01.WNL.0000073623.84147.A8
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448–52.
pubmed: 12640446
doi: 10.1038/nm840
Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol. 2004;14:11–20.
pubmed: 14997933
doi: 10.1111/j.1750-3639.2004.tb00493.x
Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103:5048–53.
pubmed: 16549802
pmcid: 1458792
doi: 10.1073/pnas.0506209103
Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW. Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer’s mice. Neurobiol Dis. 2006;23:351–61.
pubmed: 16733088
doi: 10.1016/j.nbd.2006.03.008
Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Aβ-specific Th2 cells provide cognitive and pathological benefits to Alzheimer’s mice without infiltrating the CNS. Neurobiol Dis. 2009;34:63–70.
pubmed: 19167499
pmcid: 5546306
doi: 10.1016/j.nbd.2008.12.015
Jung M, Lee S, Park S, Hong J, Kim C, Cho I, Sohn HS, Kim K, Park IW, Yoon S, et al. A Therapeutic Nanovaccine that Generates Anti-Amyloid Antibodies and Amyloid-specific Regulatory T Cells for Alzheimer’s Disease. Adv Mater. 2023;35:e2207719.
pubmed: 36329674
doi: 10.1002/adma.202207719
Pinti M, Appay V, Campisi J, Frasca D, Fulop T, Sauce D, Larbi A, Weinberger B, Cossarizza A. Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016;46:2286–301.
pubmed: 27595500
pmcid: 5156481
doi: 10.1002/eji.201546178
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, et al. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating Aducanumab in patients with early Alzheimer Disease. JAMA Neurol. 2022;79:13–21.
pubmed: 34807243
doi: 10.1001/jamaneurol.2021.4161
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.
pubmed: 36449413
doi: 10.1056/NEJMoa2212948
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367–85.
pubmed: 21784348
pmcid: 3693547
doi: 10.1016/j.jalz.2011.05.2351
Francesca A, Pawel K, Scott A: Accelerated brain volume loss caused by anti–β-amyloid drugs: a systematic review and meta-analysis. Neurology 2023: https://doi.org/10.1212/WNL.0000000000207156 .
Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T Cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762.
pubmed: 35309357
pmcid: 8928448
doi: 10.3389/fimmu.2022.835762
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
pubmed: 33824268
pmcid: 8024391
doi: 10.1038/s41408-021-00459-7
Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature. 2020;577:399–404.
pubmed: 31915375
pmcid: 7445078
doi: 10.1038/s41586-019-1895-7
Oberstein TJ, Taha L, Spitzer P, Hellstern J, Herrmann M, Kornhuber J, Maler JM. Imbalance of circulating T(h)17 and regulatory T Cells in Alzheimer’s disease: a case control study. Front Immunol. 2018;9:1213.
pubmed: 29915582
pmcid: 5994416
doi: 10.3389/fimmu.2018.01213
Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T Cell subsets in mild Alzheimer’s disease. J Alzheimers Dis. 2009;17:91–103.
pubmed: 19494434
doi: 10.3233/JAD-2009-1015
Anderson KM, Olson KE, Estes KA, Flanagan K, Gendelman HE, Mosley RL. Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration. 2014;3:25.
pubmed: 25671101
pmcid: 4323229
doi: 10.1186/2047-9158-3-25
Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni R, Clerici M. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer’s disease. Brain Behav Immun. 2011;25:539–47.
pubmed: 21167930
doi: 10.1016/j.bbi.2010.12.004
Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther. 2015;7:33.
pubmed: 25802557
pmcid: 4369837
doi: 10.1186/s13195-015-0117-2
Machhi J, Kevadiya BD, Muhammad IK, Herskovitz J, Olson KE, Mosley RL, Gendelman HE. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener. 2020;15:32.
pubmed: 32503641
pmcid: 7275301
doi: 10.1186/s13024-020-00375-7
Faridar A, Thome AD, Zhao W, Thonhoff JR, Beers DR, Pascual B, Masdeu JC, Appel SH. Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion. Brain Commun. 2020;2:fcaa112.
pubmed: 32954348
pmcid: 7472911
doi: 10.1093/braincomms/fcaa112
Faridar A, Vasquez M, Thome AD, Yin Z, Xuan H, Wang JH, Wen S, Li X, Thonhoff JR, Zhao W, et al. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease. Acta Neuropathol Commun. 2022;10:144.
pubmed: 36180898
pmcid: 9524037
doi: 10.1186/s40478-022-01447-z
Yang H, Park SY, Baek H, Lee C, Chung G, Liu X, Lee JH, Kim B, Kwon M, Choi H, et al. Adoptive therapy with amyloid-beta specific regulatory T cells alleviates Alzheimer’s disease. Theranostics. 2022;12:7668–80.
pubmed: 36451854
pmcid: 9706584
doi: 10.7150/thno.75965
Olson KE, Namminga KL, Lu Y, Thurston MJ, Schwab AD, de Picciotto S, Tse SW, Walker W, Iacovelli J, Small C, et al. Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson’s disease. Biomaterials. 2021;272:120786.
pubmed: 33839625
pmcid: 8382980
doi: 10.1016/j.biomaterials.2021.120786
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune toleranc. Cell. 2008;133:775–87.
pubmed: 18510923
doi: 10.1016/j.cell.2008.05.009
Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184:2261–71.
pubmed: 20118279
doi: 10.4049/jimmunol.0901852
Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Yokoyama I, Mosley RL, Gendelman HE. Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer’s disease mice. J Neuroimmunol. 2018;319:80–92.
pubmed: 29573847
pmcid: 5916331
doi: 10.1016/j.jneuroim.2018.03.009
Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, Cagnard N, Holzenberger M, Piaggio E, Aucouturier P, Dorothee G. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139:1237–51.
pubmed: 26912648
doi: 10.1093/brain/awv408
Olson KE, Namminga KL, Lu Y, Schwab AD, Thurston MJ, Abdelmoaty MM, Kumar V, Wojtkiewicz M, Obaro H, Santamaria P, et al. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson’s disease. EBioMedicine. 2021;67:103380.
pubmed: 34000620
pmcid: 8138485
doi: 10.1016/j.ebiom.2021.103380
Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, Shetty BLD, Lu Y, Estes KA, Standaert DG, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis. 2017;3:10.
pubmed: 28649610
pmcid: 5445595
doi: 10.1038/s41531-017-0013-5
Browne TC, McQuillan K, McManus RM, O’Reilly JA, Mills KH, Lynch MA. IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190:2241–51.
pubmed: 23365075
doi: 10.4049/jimmunol.1200947
Olson KE, Abdelmoaty MM, Namminga KL, Lu Y, Obaro H, Santamaria P, Mosley RL, Gendelman HE. An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Transl Neurodegener. 2023;12:26.
pubmed: 37217980
pmcid: 10201023
doi: 10.1186/s40035-023-00361-1
Machhi J, Yeapuri P, Lu Y, Foster E, Chikhale R, Herskovitz J, Namminga KL, Olson KE, Abdelmoaty MM, Gao J, et al. CD4+ effector T cells accelerate Alzheimer’s disease in mice. J Neuroinflammation. 2021;18:272.
pubmed: 34798897
pmcid: 8603581
doi: 10.1186/s12974-021-02308-7
Herskovitz J, Hasan M, Patel M, Blomberg WR, Cohen JD, Machhi J, Shahjin F, Mosley RL, McMillan J, Kevadiya BD, Gendelman HE. CRISPR-cas9 mediated exonic disruption for HIV-1 elimination. EBioMedicine. 2021;73: 103678.
pubmed: 34774454
pmcid: 8633974
doi: 10.1016/j.ebiom.2021.103678
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–103.
pubmed: 8810256
doi: 10.1126/science.274.5284.99
Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–3.
pubmed: 8878479
doi: 10.1038/383710a0
Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Zhang G, Mosley RL, Gelbard HA, Gendelman HE. URMC-099 facilitates amyloid-beta clearance in a murine model of Alzheimer’s disease. J Neuroinflammation. 2018;15:137.
pubmed: 29729668
pmcid: 5935963
doi: 10.1186/s12974-018-1172-y
Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A. 2011;108:E1339-1348.
pubmed: 22042871
pmcid: 3241747
doi: 10.1073/pnas.1102349108
Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010;24:3093–102.
pubmed: 20371618
pmcid: 2909296
doi: 10.1096/fj.10-155317
Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34:1060–8.
pubmed: 23040664
doi: 10.1016/j.neurobiolaging.2012.08.009
Prieur EAK, Jadavji NM. Assessing spatial working memory using the spontaneous alternation Y-maze test in aged male mice. Bio Protoc. 2019;9:e3162.
pubmed: 33654968
pmcid: 7854095
doi: 10.21769/BioProtoc.3162
Yeapuri P, Olson KE, Lu Y, Abdelmoaty MM, Namminga KL, Markovic M, Machhi J, Mosley RL, Gendelman HE. Development of an extended half-life GM-CSF fusion protein for Parkinson’s disease. J Control Release. 2022;348:951–65.
pubmed: 35738463
pmcid: 10350880
doi: 10.1016/j.jconrel.2022.06.024
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Niccoli T, Cabecinha M, Tillmann A, Kerr F, Wong CT, Cardenes D, Vincent AJ, Bettedi L, Li L, Gronke S, et al. Increased glucose transport into neurons rescues Abeta toxicity in Drosophila. Curr Biol. 2016;26:2291–300.
pubmed: 27524482
pmcid: 5026704
doi: 10.1016/j.cub.2016.07.017
Hammond TC, Lin AL. Glucose metabolism is a better marker for predicting clinical Alzheimer’s disease than amyloid or Tau. J Cell Immunol. 2022;4:15–8.
pubmed: 35373192
pmcid: 8975178
Ciccocioppo F, Lanuti P, Pierdomenico L, Simeone P, Bologna G, Ercolino E, Buttari F, Fantozzi R, Thomas A, Onofrj M, et al. The characterization of regulatory T-Cell profiles in Alzheimer’s disease and Multiple sclerosis. Sci Rep. 2019;9:8788.
pubmed: 31217537
pmcid: 6584558
doi: 10.1038/s41598-019-45433-3
Abdelmoaty MM, Yeapuri P, Machhi J, Lu Y, Namminga KL, Kadry R, Lu E, Bhattarai S, Mosley RL, Gendelman HE. Immune senescence in aged APP/PS1 mice. NeuroImmune Pharm Ther. 2023;2:317–30.
pubmed: 38023614
pmcid: 10659760
doi: 10.1515/nipt-2023-0015
Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465.
pubmed: 29845093
pmcid: 5961523
doi: 10.1212/NXI.0000000000000465
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217:459–72.
pubmed: 29196460
pmcid: 5800817
doi: 10.1083/jcb.201709069
Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19:622–35.
pubmed: 30206328
pmcid: 7255106
doi: 10.1038/s41583-018-0057-5
Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AH, Verveer M, de Groot LR, Smith VD, Rangarajan S, et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE. 2012;7:e42823.
pubmed: 22912745
pmcid: 3418292
doi: 10.1371/journal.pone.0042823
Monterey MD, Wei H, Wu X, Wu JQ. The Many Faces of Astrocytes in Alzheimer’s Disease. Front Neurol. 2021;12:619626.
pubmed: 34531807
pmcid: 8438135
doi: 10.3389/fneur.2021.619626
Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, Sciancalepore F, Corbo M, Lombardo FL, Bacigalupo I, et al. Safety and efficacy of monoclonal antibodies for Alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis. 2022;87:101–29.
pubmed: 35275549
pmcid: 9198746
doi: 10.3233/JAD-220046
Hu D, Xia W, Weiner HL. CD8(+) T cells in neurodegeneration: friend or foe? Mol Neurodegener. 2022;17:59.
pubmed: 36056406
pmcid: 9437386
doi: 10.1186/s13024-022-00563-7
Machado-Santos J, Saji E, Troscher AR, Paunovic M, Liblau R, Gabriely G, Bien CG, Bauer J, Lassmann H. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141:2066–82.
pubmed: 29873694
pmcid: 6022681
doi: 10.1093/brain/awy151
Smolders J, Heutinck KM, Fransen NL, Remmerswaal EBM, Hombrink P, Ten Berge IJM, van Lier RAW, Huitinga I, Hamann J. Tissue-resident memory T cells populate the human brain. Nat Commun. 2018;9:4593.
pubmed: 30389931
pmcid: 6214977
doi: 10.1038/s41467-018-07053-9
Liston A, Dooley J, Yshii L. Brain-resident regulatory T cells and their role in health and disease. Immunol Lett. 2022;248:26–30.
pubmed: 35697195
doi: 10.1016/j.imlet.2022.06.005
Chwojnicki K, Iwaszkiewicz-Grześ D, Jankowska A, Zieliński M, Łowiec P, Gliwiński M, Grzywińska M, Kowalczyk K, Konarzewska A, Glasner P, et al. Administration of CD4+CD25highCD127−FoxP3+ regulatory T cells for relapsing-remitting Multiple sclerosis: a phase 1 study. BioDrugs. 2021;35:47–60.
pubmed: 33400237
doi: 10.1007/s40259-020-00462-7
Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20:158–72.
pubmed: 31811270
doi: 10.1038/s41577-019-0232-6
Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–90.
pubmed: 10605010
doi: 10.4049/jimmunol.164.1.183
Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro–expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455–65.
pubmed: 15184499
pmcid: 2211775
doi: 10.1084/jem.20040139
Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T Cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199:1467–77.
pubmed: 15184500
pmcid: 2211787
doi: 10.1084/jem.20040180
Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol. 2009;39:1108–17.
pubmed: 19350586
doi: 10.1002/eji.200839073
Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MA, Hannen RF, Cooper D, Marelli-Berg FM, Watt FM, Lechler RI, Maher J, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17:931–43.
pubmed: 28027623
doi: 10.1111/ajt.14185
Bezie S, Charreau B, Vimond N, Lasselin J, Gerard N, Nerriere-Daguin V, Bellier-Waast F, Duteille F, Anegon I, Guillonneau C. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv. 2019;3:3522–38.
pubmed: 31730699
pmcid: 6880915
doi: 10.1182/bloodadvances.2019000411
Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3:83ra42.
pubmed: 21593402
pmcid: 3776382
doi: 10.1126/scitranslmed.3002076
Veerapathran A, Pidala J, Beato F, Yu X-Z, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118:5671–80.
pubmed: 21948174
pmcid: 3217366
doi: 10.1182/blood-2011-02-337097
Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS ONE. 2010;5:e11726.
pubmed: 20668510
pmcid: 2908680
doi: 10.1371/journal.pone.0011726
Hull CM, Nickolay LE, Estorninho M, Richardson MW, Riley JL, Peakman M, Maher J, Tree TI. Generation of human islet-specific regulatory T cells by TCR gene transfer. J Autoimmun. 2017;79:63–73.
pubmed: 28117148
doi: 10.1016/j.jaut.2017.01.001
Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother. 2011;34:343–52.
pubmed: 21499127
pmcid: 3100770
doi: 10.1097/CJI.0b013e3182187600
Gershon RK, Kondo K. Infectious immunological tolerance. Immunology. 1971;21:903–14.
pubmed: 4943147
pmcid: 1408252
Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci. 2012;69:1997–2008.
pubmed: 22205213
doi: 10.1007/s00018-011-0907-z
Legoux FP, Lim JB, Cauley AW, Dikiy S, Ertelt J, Mariani TJ, Sparwasser T, Way SS, Moon JJ. CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity. 2015;43:896–908.
pubmed: 26572061
pmcid: 4654997
doi: 10.1016/j.immuni.2015.10.011
Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T Cell tolerance. J Immunol. 2005;175:7085–91.
pubmed: 16301609
doi: 10.4049/jimmunol.175.11.7085
Silva-Filho JL, Caruso-Neves C, Pinheiro AAS. IL-4: an important cytokine in determining the fate of T cells. Biophys Rev. 2014;6:111–8.
pubmed: 28509961
pmcid: 5427811
doi: 10.1007/s12551-013-0133-z
Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer’s disease. J Alzheimers Dis. 2008;14:147–59.
pubmed: 18560127
doi: 10.3233/JAD-2008-14203
Haar HJvd, Burgmans S, Jansen JFA, Osch MJPv, Buchem MAv, Muller M, Hofman PAM, Verhey FRJ, Backes WH. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2016;281:527–35.
pubmed: 27243267
doi: 10.1148/radiol.2016152244
Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020;19:951–62.
pubmed: 33098804
doi: 10.1016/S1474-4422(20)30314-8
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 2018;17:241–50.
pubmed: 29397305
pmcid: 5816717
doi: 10.1016/S1474-4422(18)30028-0
Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78–87.
pubmed: 20139997
doi: 10.1038/nrneurol.2009.217
Mittal K, Eremenko E, Berner O, Elyahu Y, Strominger I, Apelblat D, Nemirovsky A, Spiegel I, Monsonego A. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates Alzheimer pathology. iScience. 2019;16:298–311.
pubmed: 31203186
pmcid: 6581663
doi: 10.1016/j.isci.2019.05.039
Xie L, Choudhury GR, Winters A, Yang SH, Jin K. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10. Eur J Immunol. 2015;45:180–91.
pubmed: 25329858
doi: 10.1002/eji.201444823